June 17, 2015 - ZOLL LifeVest Wearable Defibrillator to Be Showcased at EHRA EUROPACE-CARDIOSTIM 2015


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
[email protected]


June 17, 2015—CHELMSFORD, MASS.—ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will display the LifeVest® Wearable Defibrillator, along with sudden cardiac death (SCD) education and screening tools, in Booth C-210 at the EHRA EUROPACE-CARDIOSTIM 2015, being held from 21-24 June in Milan, Italy.

The LifeVest will be discussed during the following scientific sessions:

  • A satellite symposium entitled “One in 14 Patients Require Arrhythmia Intervention: Remote Patient Management with the Wearable Cardioverter Defibrillator,” will be chaired by PD Dr. Johannes Sperzel, Kerckhoff Klinik Bad Nauheim, and Prof. Jean-Claude Deharo, CHU de Marseille, and presented by Dr. Oliver Przibille, CCB Frankfurt, and PD Dr. Jan Steffel, USZ Zurich, Tuesday, 23 June, 12:45-13:45, Venezia Room.
  • Dr. David Duncker, MHH Hanover, will present “Quality of Life, Biomarkers and ICD Indications in Patients with a Wearable Cardioverter Defibrillator—Preliminary Results of a Prospective Trial with One Year of Follow Up,” Monday, 22 June, 14:00, Poster Session 4, Poster #P1010.
  • Prof. Dr. Med. Dr. Phil. Anil-Martin Sinha, Sana Klinikum Hof, will present “Wearable Cardioverter Defibrillator Reduces Implantation Rate of ICD in Patients with High Risk for Life-Threatening Cardiac Arrhythmias,” Monday, 22 June, 14:00, Poster Session 4, Poster #P1014.
  • Ramu Perumal, PhD, ZOLL, will present “Ischemia Prior to Ventricular Tachyarrhythmia Does Not Affect Survival in Acute Myocardial Infarction Patients Treated with a Wearable Cardioverter Defibrillator,” Wednesday, 24 June, 8:30, Poster Session 7, Poster #P1659.

The LifeVest protects patients at risk for SCD. It is used for a wide range of patient conditions or situations, including following a myocardial infarction, before or after coronary revascularization, and for those with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

In the WEARIT-II prospective registry of 2,000 patients prescribed the LifeVest, the sustained VT/VF event rate was high with 22 events per 100 patient-years—2.1% of patients had a VT/VF event.1 One in 14 patients experienced a clinically meaningful arrhythmia requiring intervention while wearing the LifeVest.1 The LifeVest Network online patient data management system provides customizable tools for physicians and clinicians to access these captured arrhythmias, like atrial fibrillation or non-sustained ventricular tachyarrhythmias, and determine the appropriate intervention.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

1Kutyifa V. et al. Results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry), presented as Late Breaking Clinical Trial at the European Society of Cardiology Congress, September 3, 2014.

Copyright © 2015 ZOLL Medical Corporation. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.